SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 15, 2026

MLYS

Mineralys Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago
Insider cluster: 2 insiders, $679K total
Actionable Insight • Neutral

Sales are immaterial relative to market cap and consistent with post-vesting liquidity. No bearish signal. Monitor next quarterly filing for any change in insider sentiment or material corporate developments.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$27.08
T+0 close · Jul 15, 2026 · via day close
Latest settled
−13.70%
T+60 · $23.37
Vs SPY
−17.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 16 $27.08entry
  2. T+1 · 4mo ago +0.04%α +1.03% · $27.09
  3. T+5 · 4mo ago −0.30%α +1.38% · $27.00
  4. T+20 · 3mo ago −3.66%α −7.27% · $26.09
  5. T+60 · 6w ago −13.70%α −17.41% · $23.37
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Jon Congleton and CMO David Malcom Rodman sold a combined $679K of MLYS stock in open-market sales on July 13, 2026, following derivative exercises by the CMO. At a $2.3B market cap, the sales represent ~0.03% of market cap, well below the 0.1% threshold for materiality. The CMO's exercises were non-cash events; the sales appear to be routine post-vesting liquidity transactions, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$679.0K
Insiders
2

Key Facts

  • CEO Jon Congleton sold 10,700 shares at $27.24 for $291K on July 13, 2026.
  • CMO David Malcom Rodman sold 14,058 shares at $27.58 for $388K on July 13, 2026.
  • CMO also exercised multiple derivative tranches (non-cash) on July 13, 2026.
  • Total open-market sales: $679K, representing ~0.03% of MLYS's $2.3B market cap.
  • No insider purchases were reported in the cluster window.

Financial Impact

Total insider sales of $679K represent ~0.03% of market cap, trivial and routine.

insider ownership

Risk Factors

  • Insider sales could increase if additional vesting events occur.
  • No purchases to offset the selling pattern.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MLYS-1784163533883

Track record

35 reports on MLYS

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.

Filters
  1. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
  2. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
  3. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
  4. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
  6. Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
  7. Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
  8. Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
  9. Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
  10. Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
Showing 10 of 35

US Market Status

Market Closed · Opens in 8h 32m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 15, 2026